Member Info for neilrich3

Lets hope that Guillermo Raimondo pulls a £75 million order out of the hat from the Government of Chilie.

Why would your Chief Commercial Officer, an executive member of management, be based in Chilie of all places.....seems a bit odd to me.

Sir David King, former chief scientific adviser to the government, has raised concerns about a third wave of infections in Chile.

He told Sky News: "Chile is a country where the rate of vaccination amongst the population was third highest in the world - they were ahead of us in terms of the number of people who have had the vaccine - and they're suddenly now into a third wave.

"They now have 7,600 cases a day and the total number of people in Chile now who have Covid-19 is over a million.

"So what has happened in Chile is very, very surprising - a high percentage of people have been vaccinated, but here's a variant of the disease coming through the country."

Can't agree....the profit warning came under Q1 trading update and 2021 outlook.

Takeover for sure, couple of months back we'd never have accepted an offer of £12 a share, however now that the price has been driven down to £4....when that £12 offer arrives, the deal is a dead cert.

That's a very good point, there was no need to state that profits may be lower, as no guidance had been issued previously.

There's no issue with the test kits, any issues with regards to quality would have been rectified.

Can't imagine possible in the run up to the results.

Couldn't possibly be the value of the contract, the machines are being used and PROmate has been very well received.

The global COVID-19 diagnostics market size is estimated at USD 84.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027.

Contractual dispute does not automatically equal legal case.

£2 would bring the market cap down to £140 million....that's the cash NCYT have on deposit at the bank.

With margins greater than 80% there's room to bring prices down yet remain very profitable.

Think that you've hit the nail on the head and has been missed by many, the fact that the trading update informed us that 50% of our sales were non-DHSC. Imagine if we'd had all our eggs in the one basket! What would be nice now....perhaps an order from a foreign government or two, if the French were to place an order for 15 million PCR tests followed by a similar order from another Country.

Would love to learn more about Guillermo and what he contributing to the bottom line and whether he's on the ground alone?

From his previous role:
Linkedin 'Managed more than 4B USD in sales volume. Led 8 vice presidents managing more than 350 overall staff.'

Israel is leading the world with the vaccination, however cases are still rising daily....how do they know that? Because people are still falling ill and they're still testing!!

Interesting that you never see any vacancies for Novacyt within France, still not sure as to the role of the French arm.

The chances of an RNS Tomorrow are very slim in my opinion and quite frankly don't want one, too soon after the trading update. I'm not interested in what happens to the share price Tomorrow or next week, it's waiting game for now, more interested in where we are come September, by which time (hopefully) the borders shall be more open and allowing people to holiday abroad.

I can see very little downside from here, the days ahead mean nothing, simply traders playing games.

Attempting to find another company where annual profit exceeds £100 million, yet market cap <£300 million....that's before zero debt and cash in the bank.

Not having much luck, does such a company exist?

Don't understand those that are suggesting game over? All the research suggests that COVID testing shall continue for many years, the vaccine alone shall not win the battle.

Also, Oxford Nanopore which is about to float and similar size diagnostics firms which are being taken over at valuations far in excess of our Market Cap.

After Friday's fall you think that this company had been trading on a high multiple and that NCYT was loosing money whilst servicing a large amount of debt, fortunately nothing could be further from the truth.

Playing around with the numbers, for me worst case scenario is revenue at £10m/month for the rest of the year, although I think we shall do better than that, we already have £72m revenue from Q1, therefore the company shall smash £100m a year in profit and have a sizeable amount of cash in the bank. None of this allows for new products, which are known to be in the pipeline.

Can't get my head around the number of vacancies at present and the implications, seems an awful lot of jobs when the company has just announced a profit warning.

It's not all bad news and I expect 2021 has some nice surprises in store. I shall continue to hold.

Pathway already taking shape, you'd think based upon the number of vacancies. Can't believe that the new long term plan was centred around the DHSC.